X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs J.B.CHEMICALS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES J.B.CHEMICALS DIVIS LABORATORIES/
J.B.CHEMICALS
 
P/E (TTM) x 33.7 13.8 244.1% View Chart
P/BV x 5.5 2.2 250.6% View Chart
Dividend Yield % 0.9 0.2 510.1%  

Financials

 DIVIS LABORATORIES   J.B.CHEMICALS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
J.B.CHEMICALS
Mar-16
DIVIS LABORATORIES/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,222318 384.2%   
Low Rs784200 393.0%   
Sales per share (Unadj.) Rs153.1148.0 103.5%  
Earnings per share (Unadj.) Rs39.919.1 209.3%  
Cash flow per share (Unadj.) Rs44.623.9 186.2%  
Dividends per share (Unadj.) Rs10.000.50 2,000.0%  
Dividend yield (eoy) %1.00.2 516.1%  
Book value per share (Unadj.) Rs201.8128.9 156.5%  
Shares outstanding (eoy) m265.4784.82 313.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.61.7 374.6%   
Avg P/E ratio x25.113.6 185.2%  
P/CF ratio (eoy) x22.510.8 208.1%  
Price / Book Value ratio x5.02.0 247.6%  
Dividend payout %25.02.6 955.5%   
Avg Mkt Cap Rs m266,26621,951 1,213.0%   
No. of employees `0009.72.7 356.1%   
Total wages/salary Rs m4,6871,841 254.6%   
Avg. sales/employee Rs Th4,175.04,590.9 90.9%   
Avg. wages/employee Rs Th481.5673.4 71.5%   
Avg. net profit/employee Rs Th1,089.3592.1 184.0%   
INCOME DATA
Net Sales Rs m40,64312,551 323.8%  
Other income Rs m749542 138.3%   
Total revenues Rs m41,39213,093 316.1%   
Gross profit Rs m14,4602,055 703.8%  
Depreciation Rs m1,233412 299.1%   
Interest Rs m2396 23.6%   
Profit before tax Rs m13,9532,088 668.2%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349469 714.0%   
Profit after tax Rs m10,6041,619 655.1%  
Gross profit margin %35.616.4 217.3%  
Effective tax rate %24.022.5 106.9%   
Net profit margin %26.112.9 202.3%  
BALANCE SHEET DATA
Current assets Rs m40,1057,778 515.6%   
Current liabilities Rs m6,5954,358 151.3%   
Net working cap to sales %82.527.2 302.6%  
Current ratio x6.11.8 340.8%  
Inventory Days Days11955 216.8%  
Debtors Days Days8180 100.8%  
Net fixed assets Rs m19,9955,713 350.0%   
Share capital Rs m531170 313.0%   
"Free" reserves Rs m53,04310,547 502.9%   
Net worth Rs m53,57410,937 489.8%   
Long term debt Rs m00-   
Total assets Rs m61,58515,574 395.4%  
Interest coverage x618.422.8 2,709.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.8 81.9%   
Return on assets %17.311.0 156.8%  
Return on equity %19.814.8 133.7%  
Return on capital %26.120.0 130.7%  
Exports to sales %048.7 0.0%   
Imports to sales %25.27.1 356.5%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs m10,259889 1,154.4%   
Fx inflow Rs m35,3846,169 573.6%   
Fx outflow Rs m10,3991,285 809.2%   
Net fx Rs m24,9854,884 511.6%   
CASH FLOW
From Operations Rs m11,4931,397 822.9%  
From Investments Rs m-11,372-320 3,550.3%  
From Financial Activity Rs m-93-1,196 7.8%  
Net Cashflow Rs m28-102 -27.8%  

Share Holding

Indian Promoters % 52.0 55.4 93.9%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 11.8 3.4 348.1%  
FIIs % 19.0 3.9 487.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 37.0 46.5%  
Shareholders   31,796 30,437 104.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT LTD.  VENUS REMEDIES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 19, 2018 10:25 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - GLENMARK PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS